Mirum reports FY 2022 LIVMARLI net product sales of $75.1M; Q4 sales up 48% QoQ

Mirum Pharmaceuticals, Inc.

Full year 2022 LIVMARLI net product sales $75.1M (vs $3.1M in 2021); total revenue $77.1M.
Q4 2022 net sales up 48% vs Q3 2022; U.S. business guided for 50% growth in 2023.
Operating expenses $208.3M for 2022 (up from $192.6M in 2021); cash & investments $251.7M.
sNDA submitted for LIVMARLI in PFIC; data milestones in biliary atresia (H2 2023) and volixibat programs.
Capital raises net $121.9M since Jan 2022; net royalty obligations reduced via Satiogen acquisition.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.